PYC-001

PreclinicalSmall molecule

PPYC Therapeutics

PYC-001 is one of 3 small molecule programs targeting Optic Atrophy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Optic AtrophyActive, not recruiting

OPA1 Gene MutationRecruiting

Optic AtrophyPhase 1/Phase 2

Active, not recruiting

OPA1 Gene MutationPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Optic Atrophy

#DrugCompanyPhaseTrials

Nicotinamide

MMetro International Biotech, LLC

Phase 3

1 2

Epoetin Beta

PYC-001

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Optic Atrophy

NCT06461286

Q4 2029

PreclinicalRecruiting

OPA1 Gene Mutation

NCT06970106

Clinical

Trials by Indication[1]

Optic Atrophy1 trial

SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)

Active, not recruiting·PPYC Therapeutics·Phase 1·NCT06461286·18 enrolled

OPA1 Gene Mutation1 trial

A Phase 1b Open-Label, Randomized, Single Dose and Repeat Dose Study to Evaluate the Single and Repeat Dose Safety and Tolerability of Intravitreally Administered PYC-001 in Participants With Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy

Recruiting·PPYC Therapeutics·Preclinical·NCT06970106·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PYC-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PYC-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PYC-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PYC Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPYC Therapeutics

PYC-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2029

Trials by Indication[1]

Optic Atrophy1 trial

OPA1 Gene Mutation1 trial

References

Drug Info

Quick Facts

Related News